Dapagliflozin 5 mg/5 mg, Sitagliptin 50 mg/50 mg, Metformin (IR) 500 mg/1000 mg Tablet

Dapagliflozin 5 mg/5 mg, Sitagliptin 50 mg/50 mg, Metformin (IR) 500 mg/1000 mg Tablet
Product Description

DCGI approval with Windlas

Read more Show less

Windlas Biotech Limited

  • IN
  • 2022
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Distributor/Import Export
Pharmaceutical company
Primary activities
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Nutraceuticals
View company profile
Categories
more categories Show less

Windlas Biotech Limited

  • IN
  • 2022
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Distributor/Import Export
Pharmaceutical company
Primary activities
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Nutraceuticals
View company profile

More Products from Windlas Biotech Limited (3)

  • Linagliptin 5mg + Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg Tablet

    Product Linagliptin 5mg + Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg Tablet

    Fixed dose combination of Dapagliflozin and Linagliptin tablet can be used as a superior treatment alternative in patients with type 2 diabetes mellitus inadequately controlled on Metformin. Despite of their distinct mechanism of actions, these drugs act collaboratively by decreasing the glycaemic index...
  • Mirabegron (ER) 25 mg/50 mg and Solifenacin 5 mg/5 mg Tablet

    Product Mirabegron (ER) 25 mg/50 mg and Solifenacin 5 mg/5 mg Tablet

    Fixed dose combination (FDC) of Mirabegron (Extended release) and Solifenacin tablet can be used for the treatment of overactive bladder and to control the frequent urination. These drugs act together by their distinct mechanism of action that provide clear improvement and reduce side effects of m...
  • Rosuvastatin 40 mg and Ezetimibe 10 mg FDC Tablets

    Product Rosuvastatin 40 mg and Ezetimibe 10 mg FDC Tablets

    Fixed dose combination of Rosuvastatin and Ezetimibe can be a superior alternative for the treatment of patients with primary hypercholesterolemia. The lipid lowering efficacy of combination therapy with Rosuvastatin and Ezetimibe is greater than that of their monotherapy.